About Us

Baird Downgrades Sarepta Therapeutics To Neutral

By: via Benzinga
Analysts at Baird downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform to Neutral. The price target for Sarepta ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.